CRISPR Therapeutics and Vertex Pharmaceuticals announce FDA RMAT designation granted to CTX001 to treat severe hemoglobinopathies

The US FDA’s Center for Drug Evaluation and Research. (Credit: The U.S. Food and Drug Administration)